A Controversial Decision Impacting the Hemp Industry
Introduction: A turning point for the CBD market in Italy
In April 2025, Italy took a radical decision regarding cannabidiol (CBD), classifying it as a narcotic substance. This measure came as a shock to the Italian hemp industry, CBD producers and consumers alike. The government's stated aim is to limit access to this cannabis-derived product by subjecting it to restrictions similar to those for other drugs. The ban has affected CBD-based products such as oils, capsules and other forms of consumption, reserving them for pharmacies and requiring a medical prescription.
An Important Legislative Change: CBD now considered a narcotic
The ban on CBD was introduced by a government decree in April 2025, which changed the legal classification of CBD in the country. From now on, all oral cannabidiol preparations, including CBD oils, capsules and tinctures, must be prescribed by a doctor and sold exclusively in pharmacies. As a result, CBD products previously available online, in specialist stores or in some physical stores, have disappeared from the shelves.
This measure follows an administrative decision classifying CBD as a narcotic substance, pursuant to the Presidential Decree of October 9, 1990. Under this decree, any oral preparation of CBD is now considered a controlled substance in Italy, on a par with more conventional drugs, despite scientific evidence indicating that CBD has no psychoactive effects.
Reactions and Legal Challenges: An industry in crisis
The announcement of this ban was poorly received by many players in the Italian CBD market, including growers, retailers and consumer rights advocates. The Association of Hemp Entrepreneurs (ICI - Imprenditori Canapa Italia) reacted swiftly, filing an appeal with the Lazio Regional Administrative Tribunal (TAR) to challenge the new legislation.
Their arguments are based on the lack of solid scientific evidence that would justify the classification of CBD as a narcotic. Indeed, numerous studies have shown that CBD, in appropriate doses, is not only non-psychoactive, but also beneficial in treating a variety of conditions such as anxiety, chronic pain, or even improving sleep quality. Italy's CBD industry argues that the decision is unjustified and risks isolating the country from the rest of the European market, where CBD is widely considered legal.
Consequences for the CBD Industry: A Threat to Local Businesses
Italy was one of the most dynamic markets for CBD in Europe, with growing demand for natural products and alternatives to traditional medicines. However, this ban could have serious economic consequences. Many companies specializing in the cultivation, production and sale of CBD products are likely to face sudden closure or massive loss of revenue.
Small local businesses, particularly those that specialized in selling CBD in the form of oils, creams, capsules and other derivatives, are the most vulnerable to this legislation. Merchants who have been involved in this sector risk seeing their business undermined, as they are unable to sell their products legally. Furthermore, exporting CBD products could become a challenge, as many European countries may be reluctant to trade with Italy due to this new restrictive legislation.
The European Context: Italy out of step with the European Union
Italy is not the only European nation to have legislated on CBD. However, its decision to completely ban the sale of CBD without a doctor's prescription is at odds with legislation in many other European countries. Indeed, countries such as France, Germany, the UK and the Netherlands have adopted regulations that allow CBD products to be sold in specialist stores and online, as long as the products comply with certain THC concentration limits (less than 0.2%).
In addition, the Court of Justice of the European Union (CJEU) recently ruled in favor of the free movement of CBD products within the European Union, stating that a member state cannot prohibit the sale of CBD products if they do not present a risk to public health. Italy is therefore out of step with this position, which could lead it to review its decision in the wake of ongoing legal challenges.
The Scientific Debate: Why is CBD Not a Narcotic?
One of the major arguments against this ban is the lack of scientific justification. Unlike THC, CBD has no psychoactive effects. It does not alter mental states or create dependency. Numerous studies have shown that CBD has therapeutic virtues, notably in the treatment of anxiety, pain, inflammation, sleep disorders, and even neurological conditions such as epilepsy. This evidence supports the idea that CBD should not be treated in the same way as other cannabis substances.
Professor Giovanni Ciallella, an expert in forensic medicine and former director at the University of Rome La Sapienza, has publicly supported the idea that the classification of CBD as a narcotic has no solid scientific basis. According to him, this decision could be seen as a step backwards for public health, by limiting access to a natural product with multiple virtues.
What's next?
The appeal lodged by the Association des Entrepreneurs du Chanvre and other industry groups has raised hopes that the ban will be overturned or modified. The Tribunal Administratif Régional (TAR) has already suspended the application of the decree, offering a temporary respite to the industry. On October 24, 2025, a hearing will be held to discuss the legislative future of CBD in Italy.
It is possible that legislative changes will be made to allow for more flexible regulation, adapted to recent scientific discoveries concerning the benefits of CBD. CBD advocates hope that this decision will not be the end of a promising industry, but rather a catalyst for further dialogue on the regulation and acceptance of cannabis products across Europe.
Conclusion: An evolution to follow closely
Italy's CBD ban represents a milestone in the legislative evolution of cannabis in Europe. As Italy stands at a legislative crossroads, the CBD industry remains determined to defend its products and guarantee legitimate, safe access to cannabidiol. The court case could well define the future of the CBD market in Italy, and potentially influence future European legislation.
